US pumps more cash into BioCryst Ebola antiviral
This article was originally published in Scrip
Executive Summary
The National Institute of Allergy and Infectious Diseases (NIAID) has infused more cash into BioCryst Pharmaceuticals' experimental Ebola drug BCX4430, which will give the firm the boost it needs to move forward with testing an intramuscular formulation of the antiviral.